Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer's disease; and ALN-HTT02 that is in phase I clinical trial for Huntington's disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam Pharmaceuticals Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Danaher (DHR – Research Report), Nurix Therapeutics ...

Analysts Are Bullish on These Healthcare Stocks: Danaher (DHR), Nurix Therapeutics (NRIX)

In a report released today, Cory Kasimov from Evercore ISI maintained a Buy rating on Alnylam Pharma, with a price target of $515.00. According to ...

Evercore ISI Sticks to Its Buy Rating for Alnylam Pharma (ALNY)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alnylam Pharma (ALNY – Research Report) and Foghorn ...

Analysts Are Bullish on Top Healthcare Stocks: Alnylam Pharma (ALNY), Foghorn Therapeutics (FHTX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alnylam Pharma (ALNY – Research Report), GeneDx Ho...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Alnylam Pharma (ALNY), GeneDx Holdings (WGS) and Masimo (MASI)

Oppenheimer analyst Kostas Biliouris maintained a Buy rating on Alnylam Pharma yesterday and set a price target of $500.00. The company’s shares cl...

Current Quarter	$0.81	Next Quarter	$1.62
Current Year	$1.88	Next Year	$7.24
QoQ Growth	+100.0%	YoY Growth	+285.1%
3Y EPS CAGR	+32.9%	Target Price	$491.55
Consensus	Buy	Upside	+45.0%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ALNY	$339.11	+0.31%	1.91M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ALNY	$339.11	+0.3%	1.91M
3
4
5
6

ALNY

ALNY

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Alnylam Pharmaceuticals Inc. Data in Excel

Get Alnylam Pharmaceuticals Inc. Data in Excel